

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Technology Appraisal guidance no.'s 61; Capecitabine and tegafur uracil for metastatic colorectal cancer and 176; Cetuximab for the first line treatment of metastatic colorectal cancer

Provisional matrix of consultees and commentators

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| <p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Merck Sorono (tegafur uracil, cetuximab) • Roche Products (capecitabine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Beating Bowel Cancer • Black Health Agency • Bladder and Bowel Foundation • Bowel Cancer UK • CANCERactive • Cancer Black Care • Cancer Equality • Chinese National Healthy Living Centre • Colostomy Association • Counsel and Care • Equalities National Council • Europacolon • Helen Rollason Heal Cancer Charity • IA: Ileostomy and Internal Pouch Support Group • Lynn's Bowel Cancer Campaign • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • Muslim Health Network • Ostomy Lifestyle Centre • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care • Tenovus | <p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Actavis UK (irinotecan, oxaliplatin) • Goldshields Pharmaceuticals (calcium folinate) • Hospira UK (calcium folinate, fluorouracil, irinotecan, calcium levofolinate, oxaliplatin) • Medac UK (disodium folinate, fluorouracil, irinotecan, oxaliplatin) • Mylan UK (calcium folinate, irinotecan, oxaliplatin) • Pfizer (irinotecan, calcium folinate, calcium levofolinate) • Roche Diagnostics |

| Consultees | Commentators (no right to submit or appeal) |
|--|---|
| <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Coloproctologists of Great Britain • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Association of Surgical Oncology • British Geriatrics Society • British Institute for Radiology • British Oncological Association (BOA) • British Psychosocial Oncology Society (BPOS) • British Society of Gastroenterology • Cancer Network Pharmacists Forum • Cancer Research UK • Pelican Cancer Foundation • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • United Kingdom Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Bolton • NHS Enfield • Welsh Assembly Government | <ul style="list-style-type: none"> • Roche Products (capecitabine) • Sanofi Aventis (oxaliplatin) • Teva UK (calcium folinate, irinotecan, oxaliplatin) • Winthrop (oxaliplatin) • Wockhardt UK (calcium folinate, fluorouracil, oxaliplatin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bowel & Cancer Research • CORE (Digestive Disorders Foundation) • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Collaborating Centre for Cancer <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the *British National Formulary*, and the British Medical Association).

Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.